Key points are not available for this paper at this time.
The assessment of the suitability of novel targets to intervention by different modalities, e.g. small molecules or antibodies, is increasingly seen as important in helping to select the most progressable targets at the outset of a drug discovery project.
Brown et al. (Mon,) studied this question.